| Latest | F'cast | |
|---|---|---|
| Div Yield | 3.7% | 0.0% |
| Div Cover | 0.9 | n/a |
| Op Mrgn | 4.7% | n/a |
| ROCE | 7.3% |
| Latest | F'cast | |
|---|---|---|
| P/E | 28.9 | n/a |
| PEG | n/a | n/a |
| Pr/Revenue | 0.9 | n/a |
| Pr/Book | 1.8 |
| Latest | F'cast | |
|---|---|---|
| Revenue | -10.2% | n/a |
| PBT | -90.5% | n/a |
| EPS | -67.6% | n/a |
| DPS | n/a | n/a |
| Year Ending | Revenue (£m) | Pre-tax (£m) | EPS | P/E | PEG | EPS Grth. | Div | Yield |
|---|---|---|---|---|---|---|---|---|
| 31-Mar-21 | 773.00 | 70.90 | 11.50p | 39.4 | 1.2 | +34% | n/a | 0.0% |
| 31-Mar-22 | 908.30 | 214.30 | 17.40p | 13.7 | 0.3 | +51% | 5.50p | 2.3% |
| 31-Mar-23 | 1,000.30 | 159.40 | 12.90p | 11.0 | n/a | -26% | 5.84p | 4.1% |
| 31-Mar-24 | 877.10 | 93.00 | 7.40p | 11.9 | n/a | -43% | 2.55p | 2.9% |
| 30-Mar-25 | 787.60 | 8.80 | 2.40p | 21.7 | n/a | -68% | 2.55p | 4.9% |
a. Based on UK GAAP presentation of accounts - includes discontinued activities
| Holding(s) in Company | 01-May-2026 | 07:00 | RNS |
| Total Voting Rights | 30-Apr-2026 | 08:31 | RNS |
| Holding(s) in Company | 29-Apr-2026 | 07:00 | RNS |
| Dr Martens shares tank on revenue outlook as Q3 ... | 27-Jan-2026 | ShareCast |
| Total Voting Rights | 31-Dec-2025 | ShareCast |
| Dr Martens plans price rises to offset US tariff... | 20-Nov-2025 | ShareCast |
No deals were found in the last 28 days.
| Currency | UK Pounds |
| Share Price | 60.70p |
| Change Today | -1.50p |
| % Change | -2.41 % |
| 52 Week High | 99.35 |
| 52 Week Low | 54.70 |
| Volume | 1,234,846 |
| Shares Issued | 967.93m |
| Market Cap | £587.53m |
| Beta | 0.01 |
| Value |
|
|---|
| Price Trend |
|
|---|
| Income |
|
|---|
| Growth |
|
|---|
| Latest | Previous | |
|---|---|---|
| Interim | Final | |
| Ex-Div | 05-Mar-26 | 28-Aug-25 |
| Paid | 09-Apr-26 | 08-Oct-25 |
| Amount | 0.85p | 1.70p |
| Time | Volume / Share Price |
| 16:35 | 421,760 @ 60.70p |
| 16:35 | 1,882 @ 60.70p |
| 16:35 | 1,124 @ 60.70p |
| 16:35 | 1,841 @ 60.70p |
| 16:35 | 4,476 @ 60.70p |
| Chair | Paul Mason |
| CEO | Ije Nwokori |
| CFO | Giles Wilson |
You are here: research